NASDAQ · PBYI
Healthcare · Biotechnology
$9.17
Up+$0.12 (+1.33%)
Updated Sep 11, 2026, 12:07 PM
SID Score
6.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PBYI closed at $9.17 after 20 trading sessions, up 5.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $9.01 | $9.22 | $8.90 | $9.17 | 173.46K |
| Sep 9, 2026 | $9.31 | $9.446 | $9.01 | $9.05 | 453.61K |
| Sep 8, 2026 | $9.25 | $9.57 | $8.85 | $9.39 | 365.78K |
| Sep 4, 2026 | $9.40 | $9.6374 | $9.305 | $9.55 | 185.91K |
| Sep 3, 2026 | $9.72 | $9.72 | $9.37 | $9.41 | 244.32K |
| Sep 2, 2026 | $9.40 | $9.735 | $9.28 | $9.69 | 411.94K |
| Sep 1, 2026 | $9.11 | $9.59 | $9.11 | $9.35 | 458.3K |
| Aug 31, 2026 | $9.02 | $9.20 | $8.78 | $9.11 | 242.88K |
| Aug 28, 2026 | $9.24 | $9.26 | $9.02 | $9.06 | 235.04K |
| Aug 27, 2026 | $9.01 | $9.30 | $8.95 | $9.24 | 202.72K |
| Aug 26, 2026 | $9.31 | $9.31 | $9.04 | $9.16 | 374.47K |
| Aug 25, 2026 | $9.22 | $9.38 | $9.17 | $9.32 | 303.44K |
| Aug 24, 2026 | $9.30 | $9.30 | $8.99 | $9.12 | 266.14K |
| Aug 21, 2026 | $9.20 | $9.475 | $9.07 | $9.24 | 333.62K |
| Aug 20, 2026 | $9.45 | $9.45 | $9.03 | $9.11 | 390.26K |
| Aug 19, 2026 | $9.33 | $9.51 | $9.25 | $9.49 | 262.89K |
| Aug 18, 2026 | $8.80 | $9.34 | $8.80 | $9.24 | 244.7K |
| Aug 17, 2026 | $8.80 | $8.99 | $8.621 | $8.82 | 191.91K |
| Aug 14, 2026 | $8.84 | $8.885 | $8.53 | $8.83 | 233.03K |
| Aug 13, 2026 | $8.93 | $8.965 | $8.65 | $8.71 | 263.05K |
The latest Smart Investors Daily articles mentioning PBYI.
PBYI research
Company profile and research snapshot.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | TD Cowen | Hold | — |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 23, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 20, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
LOS ANGELES, September 09, 2026--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
Yahoo · Sep 9, 2026
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SeekingAlpha · Sep 8, 2026
NERLYNX gives PBYI an established revenue stream that can support alisertibâs development into a potential second oncology franchise.
Yahoo · Sep 3, 2026
LOS ANGELES, September 03, 2026--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PBYI.
